Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 207127 + faldaprevir + ribavirin in treatment-naive genotype 1b chronic hepatitis C
2012-003533-41Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of deleobuvir, faldaprevir, ribavirin in hepatitis C virus infection, sponsored by Boehringer Ingelheim. Started Sep 2012; status: completed.
02
Drugs
deleobuvirfaldaprevirribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2012-003533-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003533-41.